Antiviral Drug Discovery

Meanwell, Nicholas A.; D’Andrea, Stanley V.; Cianci, Christopher; Dicker, Ira B.; Yeung, Kap‐Sun; Belema, Makonen; Krystal, Mark

doi:10.1002/9781118354483.ch11

Drug Discovery 2013

DOI: 10.1002/9781118354483.ch11

|View full text |Cite

Antiviral Drug Discovery

Nicholas A. Meanwell¹,

Stanley V. D’Andrea²,

Christopher Cianci³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 670 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HIV drugs based on their mode of action can be grouped as follows [47][48][49] These drugs are generally used in combination in the highly active antiretroviral therapy (HAART), also called combination antiretroviral therapy (cART). This therapy is able to control the replication of HIV-1, thus, it has radically transformed the previously fatal disease into a manageable chronic disease.…”

mentioning

confidence: 99%

Recent Advances in Influenza, HIV and SARS-CoV-2 Infection Prevention and Drug Treatment—The Need for Precision Medicine

Kálai

Pongrácz

Mátyus³

2022

Chemistry

View full text Add to dashboard Cite

Viruses, and in particular, RNA viruses, dominate the WHO’s current list of ten global health threats. Of these, we review the widespread and most common HIV, influenza virus, and SARS-CoV-2 infections, as well as their possible prevention by vaccination and treatments by pharmacotherapeutic approaches. Beyond the vaccination, we discuss the virus-targeting and host-targeting drugs approved in the last five years, in the case of SARS-CoV-2 in the last one year, as well as new drug candidates and lead molecules that have been published in the same periods. We share our views on vaccination and pharmacotherapy, their mutually reinforcing strategic significance in combating pandemics, and the pros and cons of host and virus-targeted drug therapy. The COVID-19 pandemic has provided evidence of our limited armamentarium to fight emerging viral diseases. Novel broad-spectrum vaccines as well as drugs that could even be applied as prophylactic treatments or in early phases of the viremia, possibly through oral administration, are needed in all three areas. To meet these needs, the use of multi-data-based precision medicine in the practice and innovation of vaccination and drug therapy is inevitable.

show abstract

mentioning

confidence: 99%

Recent Advances in Influenza, HIV and SARS-CoV-2 Infection Prevention and Drug Treatment—The Need for Precision Medicine

Kálai

Pongrácz

Mátyus³

2022

Chemistry

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Antiviral Drug Discovery

Cited by 1 publication

References 670 publications

Recent Advances in Influenza, HIV and SARS-CoV-2 Infection Prevention and Drug Treatment—The Need for Precision Medicine

Recent Advances in Influenza, HIV and SARS-CoV-2 Infection Prevention and Drug Treatment—The Need for Precision Medicine

Contact Info

Product

Resources

About